EFFICACY AND SAFETY OF THE NOVEL ORAL ANTICOAGULANTS FOR PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN ATRIAL FIBRILLATION
https://doi.org/10.15829/1560-4071-2017-6-158-163
Abstract
Atrial fibrillation (AF) is one of the most prevalent rhythm disorders and might be associated with the high risk of thromboembolic complications, including stroke. For risk estimation, of the thrombotic complications, a variety of scores has been implemented, including CHA2DS2-VASc Score. According to the European Society of Cardiology Guidelines on AF management (2016), males showing more than 2 points, and females with more than 3 points by CHA2DS2-VASc, for embolism prevention, it is recommended to prescribe novel oral anticoagulants (NOAC). NOAC are effective and relatively safe comparing to vitamin K antagonists (VKA), are convenient being taken per os, do not have necessity of individual dosing, have rapid onset of the maximum effect (in several hours) and predictable effect in relation to dose. Among drugs from this group, dabigatran can be highlighted, which has in comparative studies shown not only high efficacy, but is the safest among all NOAC, as it does rarely lead to hemorrhagic complications and is the only NOAC for now, with the developed and available neutralizing agent — idarucizumab.
About the Authors
S. K. Zyryanov
Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
A. P. Pereverzev
Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
References
1. Anumonwo JM, Kalifa J. Risk factors and genetics of atrial fibrillation. Cardiol Clin. 2014 Nov; 32 (4): 485-94. doi: 10.1016/j.ccl.2014.07.007. Epub 2014 Aug 29.
2. Kokubo Y, Matsumoto C. Traditional Cardiovascular Risk Factors for Incident Atrial Fibrillation. Circ J. 2016 Nov 25; 80 (12): 2415-22. Epub 2016 Oct 29.
3. Dulli DA, Stanko H, Levine RL. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology. 2003 Mar; 22(2): 118-23.
4. Dolgova EL, Sokolov IM, Shvartz YuG. The problem of choosing an anticoagulant for the prevention of stroke in patients with atrial fibrillation. Medical Council, 2014; 12: 58-64 (Долгова Е. Л., Соколов И. М., Шварц Ю. Г . Проблема выбора антикоагулянта для профилактики инсульта у больных с фибрилляцией предсердий. Медицинский совет, 2014; 12: 58-64).
5. Camm AJ, Kirchhof P, Lip GY, et al. ESC Committee for Practice Guidelines, European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010; 12: 1360-420.
6. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESCEndorsed by the European Stroke Organisation (ESO). Eur Heart J. 2016 Aug 27. pii: ehw210. Available at: http://eurheartj.oxfordjournals.org/content/early/2016/08/26/eurheartj.ehw210.
7. Jones M, McEwan P, Morgan CL, et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non- valvar atrial fibrillation: a record linkage study in a large British population. Heart. 2005 Apr; 91 (4): 472-7.
8. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. ClinPharmacokinet 2008; 47: 285-95.
9. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2009 Sep 17; 361 (12): 1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30.
10. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. NEnglJMed. 2010 Nov 4; 363 (19): 1875-6. doi: 10.1056/NEJMc1007378.
11. Patel MR, Mahaffey KW, Garg J, et al., ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8; 365 (10): 883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10.
12. Granger CB, Alexander JH, McMurray JJ, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15; 365 (11): 981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27.
13. Lip GY, Larsen TB, Skjøth F, et al. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.J Am CollCardiol. 2012 Aug 21; 60 (8): 738-46. doi: 10.1016/j.jacc.2012.03.019. Epub 2012 May 9.
14. Wells G, Coyle D, Cameron Ch, et al. Safety, Effectiveness, and Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation. CADTH Therapeutic Review. Canadian Agency for Drugs and Technologies in Health; 2012 Apr 9.
15. Beloysov DYu, Afanasyeva EV. Clinical and economy analysis of dabigatran and rivaroxaban use in ischemic stroke and systemic embolism prevention in patients with non- valve atrial fibrillationin. Clinical pharmacology and therapy, 2017; 26 (3): 69-76. Russian (Белоусов Д . Ю., Афанасьева Е. В. Клинико-экономический анализ применения дабигатрана и ривароксабана для профилактики ишемического инсульта и системных тромбоэмболий у пациентов с неклапанной фибрилляцией предсердий. Клиническая фармакология и терапия, 2017, 26 (3): 69-76).
16. Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med. 2015 Aug 6; 373 (6): 511-20. doi: 10.1056/NEJMoa1502000. Epub 2015 Jun 22.
Review
For citations:
Zyryanov S.K., Pereverzev A.P. EFFICACY AND SAFETY OF THE NOVEL ORAL ANTICOAGULANTS FOR PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN ATRIAL FIBRILLATION. Russian Journal of Cardiology. 2017;(6):158-163. (In Russ.) https://doi.org/10.15829/1560-4071-2017-6-158-163
Views:
846
Email this article 